154 related articles for article (PubMed ID: 10083185)
1. Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors.
Fu F; Li W; Lu L; Fung JJ; Thomson AW; Qian S
Transplant Proc; 1999; 31(1-2):453. PubMed ID: 10083185
[No Abstract] [Full Text] [Related]
2. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555
[No Abstract] [Full Text] [Related]
3. CTLA4-Ig inhibits rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with increased lymphocyte apoptosis.
Li W; Lu L; Wang Z; Wang L; Thomson A; Fung J; Qian S
Transplant Proc; 2001; 33(1-2):246-7. PubMed ID: 11266801
[No Abstract] [Full Text] [Related]
4. Evidence that the adenoviral vector containing the CTLA4-Ig gene improves transgene expression and graft survival.
Namii Y; Hayashi S; Yokoyama I; Kobayashi T; Yasutomi M; Nagasaka T; Uchida K; Hamada H; Takagi H
Transplant Proc; 1997 May; 29(3):1738-9. PubMed ID: 9142255
[No Abstract] [Full Text] [Related]
5. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
6. Effect of CTLA4-Ig gene transfer using adenoviral vector in organ and cell transplantation.
Hayashi S; Namii Y; Kozima T; Kobayashi T; Yokoyama I; Saito I; Hamada H; Ohtsuka S; Uchida K; Takagi H
Transplant Proc; 1997 Jun; 29(4):2212. PubMed ID: 9193596
[No Abstract] [Full Text] [Related]
7. CTLA4-Ig treatment prolongs rat orthotopic liver graft survival.
Tu Y; Rehman A; Flye MW
Transplant Proc; 1997; 29(1-2):1036-7. PubMed ID: 9123186
[No Abstract] [Full Text] [Related]
8. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
9. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of corneal allograft reaction by CTLA4-Ig.
Hoffmann F; Zhang EP; Pohl T; Kunzendorf U; Wachtlin J; Bulfone-Paus S
Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):535-40. PubMed ID: 9285225
[TBL] [Abstract][Full Text] [Related]
11. Effects of locally expressed CTLA4-Ig in a pancreatic beta cell line on the accelerated graft rejection response induced by DST.
Kimura F; Gotoh M; Tanaka T; Luo Z; Miyazaki J; Monden M; Uede T; Miyasaka M
Transplant Proc; 2001; 33(1-2):552. PubMed ID: 11266954
[No Abstract] [Full Text] [Related]
12. Protection of corneal allografts by CTLA4-Ig.
Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
[TBL] [Abstract][Full Text] [Related]
13. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP
Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270
[No Abstract] [Full Text] [Related]
15. Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporine A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection.
Jordan SC; Matsumara Y; Zuo XJ; Marchevsky A; Linsley P; Matloff J
Transpl Immunol; 1996 Mar; 4(1):33-7. PubMed ID: 8762006
[No Abstract] [Full Text] [Related]
16. Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model.
Graser E; Risch K; Linsley PS; Hancock WW; Müller A; Brock J; Reinke P; Kupiec-Weglinski JW; Volk HD; Lehmann M
Transplant Proc; 1997; 29(1-2):1307-9. PubMed ID: 9123319
[No Abstract] [Full Text] [Related]
17. Adenoviral vectors containing the CTLA4IG-gene inhibit chronic rejection in heterotopically transplanted rat tracheas.
Kita Y; Li XK; Ohba M; Funeshima N; Enosawa S; Nogimura H; Ohi S; Kageyama Y; Matsushita K; Ito Y; Takahashi T; Suzuki K; Suzuki S; Kazui T
Transplant Proc; 2000 Nov; 32(7):2036-7. PubMed ID: 11120055
[No Abstract] [Full Text] [Related]
18. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients.
Sayegh MH; Zheng XG; Magee C; Hancock WW; Turka LA
Transplantation; 1997 Dec; 64(12):1646-50. PubMed ID: 9422396
[TBL] [Abstract][Full Text] [Related]
19. Blocking T-cell costimulation to prevent transplant rejection.
Zheng XG; Turka LA
Transplant Proc; 1998 Aug; 30(5):2146-9. PubMed ID: 9723421
[No Abstract] [Full Text] [Related]
20. Mitogen hypotheses revisited: enhancement of allograft tolerance and replacement of transplantation procedures in treating cancer.
Wimer BM
Cancer Biother Radiopharm; 2000 Apr; 15(2):207-9. PubMed ID: 10803327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
